If you are interested in learning more about the EPOCH clinical trial, please contact your doctor.

The purpose of the EPOCH trial is to determine if addition of TheraSphere® to standard-of-care second-line chemotherapy improves survival time and is safe.25,26

Eligible participants for this trial are patients with metastatic colorectal cancer (mCRC) of the liver who:
  • Have disease progression with first-line chemotherapy with either an oxaliplatin- or irinotecan-based regimen; and
  • Are scheduled to receive second-line chemotherapy with the alternate chemotherapy regimen.

The trial will involve approximately 340 patients at up to 100 sites worldwide, including North America, Europe, and Asia.25,26

Principal Investigators:
  • Mary Mulcahy, MD  Northwestern University, Chicago, US
  • Ricky Sharma, MD   Oxford University, UK